Datopotamab Deruxtecan provides a TROP2-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines a TROP2-directed monoclonal antibody with a deruxtecan (DXd) topoisomerase I inhibitor payload for targeted cytotoxicity and ADC studies.
Key Features and Benefits
- TROP2-Targeting ADC: Combines a TROP2-directed monoclonal antibody with a cytotoxic DXd payload specifically for targeted cancer research.
- DXd Payload: Contains a potent topoisomerase I inhibitor designed specifically for intracellular delivery through the ADC platform.
- TROP2 Recognition: Supports studies of TROP2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a tumor-selective, protease-cleavable linker specifically designed to facilitate intracellular DXd release.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of a topoisomerase I inhibitor to TROP2-expressing cancer cells.
- DNA Damage Mechanism: DXd inhibits topoisomerase I, specifically supporting research into DNA damage and ADC-mediated cytotoxic responses.
- ADC Research Platform: Enables studies of target engagement, internalization, payload release, and cellular activity.
Applications
- TROP2-Positive Cancer Research: Supports studies involving tumors with TROP2 expression.
- Breast Cancer Research: Useful for investigating TROP2-targeted ADC strategies in relevant breast cancer models.
- Lung Cancer Research: Supports studies of TROP2-directed approaches in non-small cell lung cancer and related models.
- ADC Research: Useful for studying antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Targeted Cancer Research: Supports investigation of antibody-mediated DXd delivery to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating TROP2-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of TROP2 targeting and topoisomerase I inhibition.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Datopotamab Deruxtecan combines TROP2-directed antibody targeting with a topoisomerase I inhibitor payload and specifically supports TROP2-positive cancer, breast cancer, lung cancer, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
